Q-omics provides the consensus-scored KLHL26 profile across patient tissues and cancer cell-line models. KLHL26 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, KLHL26 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, KLHL26 RNA expression shows 19,978 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, KIRC, and ACC as cancer lineages where KLHL26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KLHL26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KLHL26 survival associations across molecular data types. KLHL26 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (5) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KLHL26 RNA expression–survival associations across cancer types. High KLHL26 expression shows unfavorable associations in LGG and LIHC, but favorable associations in HNSC, KIRC, SCLC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for KLHL26 RNA expression.
This table summarizes KLHL26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for KLHL26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KLHL26 shows lower tumor expression in KIRC and KIRP and higher tumor expression in HNSC, LIHC, COAD and CHOL. The KIRC box plot shows higher KLHL26 RNA expression in normal versus tumor tissue (log2 FC = −0.592, t-test p < 0.001).
This table shows molecular features associated with KLHL26 in patient tissues and cancer cell lines. In patient samples, KLHL26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, KLHL26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and LARGE_INTESTINE.
